Medline Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $28.43B | $25.51B | $23.23B |
| Cost of Revenue | $20.91B | $18.53B | $17.35B |
| Gross Profit | $7.52B | $6.98B | $5.89B |
| Gross Margin | 26.4% | 27.3% | 25.3% |
| Operating Expenses | |||
| Research & Development | $80.0M | $67.0M | $60.0M |
| SG&A Expense | $4.52B | $4.11B | $3.87B |
| Operating Income | $2.21B | $2.15B | $1.25B |
| Operating Margin | 7.8% | 8.4% | 5.4% |
| Interest Expense | — | — | — |
| Pretax Income | $1.25B | $1.25B | $264.0M |
| Income Tax Expense | $91.0M | $46.0M | $30.0M |
| Net Income | $1.16B | $1.16B | $234.0M |
| Net Margin | 4.1% | 4.6% | 1.0% |
| EPS (Basic) | $-0.01 | — | — |
| EPS (Diluted) | $-0.01 | — | — |
| Shares Outstanding (Basic) | 810.0M | — | — |
| Shares Outstanding (Diluted) | 810.0M | — | — |
| Dividends Per Share | — | — | — |